GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for HOPE - 4

HOPE - 4

Official Title

Heart Outcomes Prevention and Evaluation 4 (HOPE-4)

Status

Ongoing

Overview

To develop, implement and evaluate an evidence-based, contextually appropriate programme for cardiovascular disease (CVD) risk assessment, treatment and control involving: (1) simplified algorithms implemented by non-physician health workers (2) single pill, fixed dose, combination therapy (Polycap) and (3) treatment supporters and e-health technology to optimize long-term medication and lifestyle adherence. This programme has the potential to reduce risk of CV deaths and CV events by 35% over approximately 6 years, as compared to usual care. The HT Phase study objective is to evaluate whether the intervention programme can substantially reduce blood pressure (BP) levels and improve hypertension (HT) control at 1 year. The HT Phase will also address associated CV risk factors, such that important reductions in CVD and estimated CVD risk can be evaluated when the study expands to the CVD Phase (6 years).

Study Design

Cluster randomized controlled, open label trial.

Primary Endpoint

Primary Outcome HT Phase: The mean difference in change in systolic BP between the intervention and control communities at 12 months.

Primary Outcome CVD Phase: Difference in major CV events [CV death, MI, stroke, CHF, CV hospitalizations (e.g. AF, unstable or new onset angina, CHF, arterial revascularization), and end-stage renal disease] at 6 years.

Number of Patients

2500

Number of Sites

50

Number of Countries

2

Study Period

2014–2015

Principal Investigator

J-D Schwalm, Salim Yusuf

Program Manager

Tara McCready

Research Coordinator

Eleanor Ng, Hadi Musa, Victoria Yabas